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Summary 
Fluoxetine HCI, 10 mg/kg ip, twice daily produced subsensitivity to the 
hypothermic effects of nicotine (base), 1 mg/kg ip, after 1 (p<0.02) and 
2 (p<0.002) weeks of treatment. Phenelzine sulfate, desipramine HCI 
and bright artificial light produced the same effect. The capacity of 
three chemically distinct classes of antidepressants and bright artificial 
light (a treatment for seasonal depression) to produce this result suggests 
that effects on nicotinic mechanisms may be involved in the mechanism 
of action of these treatments. 
Fluoxetine HCI, a selective inhibitor of the uptake of serotonin (1-3), is an effective 
antidepressant (4-6). Wong, et.al. ~7) reported that fluoxetine failed to change the 
c~oncentration dependqnt binding of [~H]-quinuclidinyl benzilate to muscarinic receptors, 
[JH]-clonidine an~ [~H]-dihydroalprenol to a2-, agd a l - ,  and ~-adrenergic receptors 
respectively, and [JH]-pyrilamine to Hi-receptors or [~H]-naloxone to opiate receptors. 
The effects of fluoxetine, and other antidepressants on nicotinic mechanisms have 
received little attention. Schofield, et.al. (8) and Slaker, et.al. (9) presented evidence that 
amitriptyline, nortiptyline and imipramine bind to sites on the ionic channel of the nicotinic 
cholinergic receptor (nAchR). We have studied the effects of four different types of 
antidepressant treatment on a nicotinic mechanism involved in the regulation of core 
temperature. These treatments include bright artificial light (a treatment for Seasonal 
Affective Disorder) (10-14), desipramine HCI (a tricyclic antidepressant), phenelzine sulfate 
(a monoamine oxidase inhibitor), and fluoxetine HCI (a chemically distinct antidepressant 
which inhibits the uptake of serotonin). We report the effects of fluoxetine on this 
mechanism here. 
Methods and Research Design 
This report includes two experiments. Experiment 1 involves the measurement of the 
change in core temperature in response to challenge with nicotine (base), lmg/kg ip, before 
and after 1 and 2 weeks of treatment with fluoxetine HCI, 10 mg/kg ip, at 0900 and 1700 
hours. Experiment 2 was a control experiment in which 8 animals were challenged with 
nicotine (base), 1 mg/kg ip, every 7 days for 3 weeks. The mean hypothermic response to 
nicotine was measured after the first and fourth injections. The objective of this 
experiment was to demonstrate that multiple injections of nicotine, at the dose used in 
Experiment 1, do not produce subsensitivity to nicotine. Both experiments involved adult, 
male Sprague-Dawley rats. Experiment 1 involved 9 animals weighing 315+8.2 g 
(mean+SEM). The second experiment involved g animals weighing 303+9.4 g (mean+SEM). 
Measurement of core bodv temperature. Model VM Mini-Mitters (Mini-Mitter Corp., 
Sun River, OR) were surgically implanted into the peritoneal cavity. These instruments emit 
radio waves at a rate directly proportional to temperature. A transistor radio set to an AM 
frequency served as a receiver. Time to emit 10 sounds was measured using a digital 
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display stop watch. This measurement was converted to temperature using a linear 
regression equation which was derived by measuring the emission rate of each instrument at 
three different  temperatures in a temperature controlled water bath. Tocco-Bradley, et.al. 
(14) established the validity of this method. 
Nicotine Challenges. Nicotine challenges were conducted at the same time of  day so as 
to control for circadian effects on temperature. The first challenge preceded the initiation 
of treatment with Fluoxetine by 24 hours. The second and third challenges occurred 
approximately 20 hours after the 14th and 28th doses of  fluoxetine respectively. 
Temperature was measured immediately prior to and every 10 minutes for 120 minutes after 
the injection of  nicotine, 1 mg/kg ip. Baseline temperature for a given challenge is defined 
as the core temperature immediately prior to the injection of nicotine. 
Pharmaceuticals. Fluoxetine HCI was provided as a gift from Lilly Laboratories. 
Nicotine was purchased from Sigma Chemical Company, (St. Louis, MO). Doses of 
fluoxetine and nicotine refer to the salt and base forms respectively. Both agents were 
administered ip on a mg/kg basis. 
Exoerimental  Design: Study I. This study was divided into three phases. I n  phase I, 
the thermosensors were implanted into 9 animals and they were then allowed 5 days to 
recover before beginning experimentation. During phase 2, the hypothermic response to 
saline, 1 mg/kg  ip, was measured. The baseline hypothermic response to nicotine, 1 mg/kg 
ip, was measured the next day. The animals then received twice daily injections (at 0900 
and 1700) of fluoxetine, 10 mg/kg ip. Twenty hours after the 14th dose of  fluoxetine, the 
animals were rechallenged with nicotine. They received a third challenge with nicotine 20 
hours after the 28th dose (14 days of  treatment). Phase 3, a drug withdrawal phase, 
extended over 7 days. At the end of this withdrawal phase, the animals were once again 
challenged with nicotine. This allowed assessment of the duration of the effect of 
fluoxetine on thermic responsiveness to nicotine after its withdrawal. 
Recovery From Fluoxeflne, 10mg/kg ip, Administered 
Surgery at 0900 and 1700 
I I I I 
DaY°f  I I I I I I I I I I I I I I I 1 I I I I I 
Experiment 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Mini-Mitters Nicotine Nicotine Nicotine 
Implanted Challenge 1 Challenge 2 Challenge 3 
at 0900 
This figure illustrates the time course of Experiment 1. Mini-Mit ters  were implanted 
on Day 0. The animals were given 5 days to recover. The sample was challenged with 
nicotine on Day 5. This provided baseline data against which data from the other nicotine 
challenges were compared. Fluoxetine, 10mg/kg i p  twice daily, was given on Days 6-19. 
The animals were rechallenged with nicotine on Days 13 and 20 at 0900. 
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Experimental  Design: Study 2. Thermosensors were implanted into 8 rats and they 
were allowed 5 days to recover before beginning experimentation. The sample then received 
nicotine, 1 mg/kg  ip, every 7 days for 21 days. The thermic response was measured every 
10 minutes for 120 minutes following the first and fourth injections of nicotine. 
Statistical Analysis. Data entering into statistical analyses were derived by calculating 
the mean difference in thermic responsiveness of  each animal across weeks. Mean 
temperature change between challenges for each animal was then used to determine 
significance of the mean change in temperature for the sample using Student's paired t-test. 
Availability of data on the ±hermit response of each animal at 12 time points, before and 
after treatment with fluoxetine, allowed us to determine whether the responsiveness of 
individual animals to nicotine was altered using Student's paired t-test. These data are 
presented for the animals used in Experiment 1. Measures of variance in the text refer to 
the standard error of the mean (SEM). 
Results 
Experiment  1: Table 1 summarizes the data for the sample. Core temperature prior to 
challenge with saline and the first through fourth challenges with nicotine was 36.5±0.19°C, 
37.1t0.18°C,37.1±0.38°C, 36.5±0.14°C and 36.5±0.14°C. The mean thermic response to 
saline was an increase in core temAoerature of 0.22±0.10°C. The sample exhibited a change 
in core temperature of  -1.41±0.24vC in response to the first nicotine challenge. This was 
highly different  from the response to saline (p<0.0002, t=6.54, df=8). The sample exhibited 
a thermic response to nicotine of -0.44±0.26°C following 1 week of treatment with 
fluoxetine. This differed from the baseline response to nicotine at the 0.002 level (t = 4.86, 
df  = 8). The thermic response to saline 0.22±0.10°C, and to nicotine 0.16±0.14°C, did not 
di f fer  after 2 weeks of treatment with fluoxetine (p>0.70, t=0.33, df=8). Finally, the 
thermic response to nicotine after 1 week of withdrawal was 0.91±0.25°C. This did not 
differ  from baseline (p>0.15, t=1.59, df=7). 
Table II summarizes the absolute difference in the mean thermic response after 2 weeks 
of treatment with fluoxetine, relative to baseline, for each animal. Eight (8) of the 9 
animals exhibited blunting of  the hypothermic response at a<0.0006. 
ExPeriment 2: The mean thermic response to nicotine, 1 mg/kg ip, was -1.37±0.23°C 
(n=8) when the sample was first challenged and -1.32±0.20°C (n=8) at the time of the fourth 
challenge (p>0.50, t=0.67, df=7). Thus, multiple injections did not produce subsensitivity to 
subsequent challenges. 
Disgussion 
Antidepressants are not recognized as having physiologically or biochemically 
significant effects on nicotinic mechanisms. However,  this report establishes that fluoxetine 
powerfully subsensitizes a nicotinic mechanism involved in the regulation of core 
temperature. This effect  is not an artifact of multiple injections of nicotine. The relevance 
of this finding is highlighted by the recent finding that phenelzine sulfate (submitted for 
publication), desipramine HCI (submitted for publication), and bright artificial light 
(submitted for publication) produce the same effect. Thus, drugs from 3 distinct chemical 
classes and a non-pharmacologic treatment of depression all blunt the hypothermic response 
to nicotine. This suggests that rather than being adventitious, this capacity may be related 
to the mechanism of action of these drugs. 
Systemically (15-17) and centrally (18-20) administered nicotine decreases core body 
temperature. Core temperature is partially regulated at the level of the hypothalamus. The 
microinjection of  acetylcholine (21,22) or cholinomimetics (23,24) into hypothalamic nuclei 
dramatically changes core temperature. The authors (15) recently reviewed the literature 
describing the use of core temperature as a dependent variable in neuropharmacological 
research and reports of  the effects of  nicotine, muscarinic agonists and other agents on core 
temperature. 
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Animal # 
TABLE 1 
Thermic Response to Nicotine, 1 mg/kg ip 
A B C D 
Saline Baseline 1 Week 2 Weeks 
0.89+0.17 -0.77+0.28 -0.51 +0.I 2 -0.28+0.10 
0.12+0.05 - 1.56+0.13 -0.85+0. I 0 0.25+0.08 
0.03+0.07 - 1.23±0.21 -0.74t0.I0 -0.26±0.10 
0.13+0. I 0 - 1.72+0.22 1.30±0.09 -0.24+0.07 
-0.16+0.05 - 1.35+0.09 -0.81 +0.12 -0.09+0.07 
0.23t0,I I -2.32±0.19 - 1.30±0. I0 0.51-+0.I 0 
0.36+0.10 -2.50+0.17 -0.93±0.I 2 0.90±0.09 
0.29+0.05 -0.85t0.18 0.29+0.12 0.14+0.04 
0.06±0,16 -0.36+0.27 -0.45+_0,30 0.50_+0,14 
MeantSEM 0.22+0.10 - 1.41:1:0.24 - 0.44+0.26 0.16_+0.14 
Probability Statements 
Absolute Change 
A > B 1.63+0.25 p<0.0002 t=6.53 
C < B 0.97+0.31 p<0.02 t=3.15 
D < B 1.57+0.32 p<0.002 t=4.86 
A = D 0.05+0.17 n.s. t=0.33 
TABLE II 
Thermic Responsiveness of Individual Animals 
(Thermic Response to 
Nicotine at Baseline) 
(Thermic Response to Nicotine after 
2 Weeks of Treatment with Fluoxetine) 
Absolute 
Animal # Mean Difference SEM p < t = df  
1 0.11 0.16 n.s. 1.11 11 
2 1.82 0.17 0.000001 10.86 11 
3 0.99 0.21 0.0006 4.83 11 
4 1.36 0.11 0.000001 11.54 11 
5 1.28 0.15 0.000003 8.79 11 
6 1.47 0.18 0.000008 7.89 11 
7 2.86 0.21 0.000001 13.48 11 
8 3.40 0.14 0.000001 24.14 II 
9 1.06 0.19 0.0002 5.46 II 
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Nicotine promotes the release of norepinephrine in the hypothalamus (25) and of 
dopamine within the mesolimbic and nigrostriatal tracts (26.) It is conceivable that the 
development of subsensitivity to the hypothermic response to nicotine is an epiphenomenon. 
That is, should treatment with antidepressants enhance noradrenergic and dopaminergic 
neurotransmission, related nicotinic mechanisms which may serve a compensatory role when 
these monoaminergic networks are dampened or inefficient, may become subsensitive. 
Determining whether the effect is an epiphenomenon or of mechanistic importance will 
require further evaluation. The array of antidepressant treatments producing this effect 
highlights potential importance! 
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